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Lung Cancer in New Zealand: Patterns of Secondary Care
and Implications for Survival
Wendy Stevens, MBBS,* Graham Stevens, MD, FRANZCR,*† John Kolbe, MBBS, FRACP,‡§
and Brian Cox, MB, ChB, PhD, FAFPHM
Introduction: The survival of patients with lung cancer in New
Zealand is poor compared with Australia and the United States. To
determine whether these poorer outcomes were related to secondary
care management or to other factors, we documented stage of disease,
comorbidities, and initial secondary care management for patients
diagnosed with lung cancer in 2004, in Auckland and Northland (New
Zealand). These data were compared with international data.
Methods: Cases were identified from regional databases and the
New Zealand Cancer Registry. Patient, tumor, and management
details were collected from clinical records.
Results: Five hundred sixty-five eligible cases were identified: 55%
were male, the median age was 69 years, 9% were never-smokers,
81% had documented comorbidity, and 32% belonged to the most
deprived socioeconomic quintile. Histopathology was non-small cell
lung cancer (NSCLC) in 70%, small-cell lung cancer (SCLC) in
13%, 2% other types, and 15% clinicoradiological diagnoses. At
presentation, 70% of NSCLC cases had locally advanced/metastatic
disease, and 65% of SCLC cases had extensive disease. Overall,
70% of cases were referred to an anticancer service, and 50%
received initial anticancer treatment. Potentially curative treatment
was received by 20% of cases: 56% stage I/II, 10% stage III
NSCLC, and 58% limited-stage SCLC.
Conclusions: This cohort was characterized by high comorbidity
and advanced disease. Although similar to the United Kingdom,
initial treatment rates were low in comparison with Australia and the
United States, despite similar stage distributions. Overall, 50% of
patients, including 30% with early-stage disease, did not receive
initial anticancer treatment. Low anticancer treatment rates may
contribute to poorer survival outcomes in New Zealand.
Key Words: Lung cancer, Clinical management, Stage, Comorbid-
ity, Survival.
(J Thorac Oncol. 2007;2: 481–493)
Lung cancer is the leading cause of cancer death in NewZealand,1–3 accounting for 19% of all deaths from cancer
in 2002 (1471 deaths).1–3 It is expected to remain a major
public health problem in New Zealand for many years.
Although lung cancer rates in males have decreased, rates in
females are increasing,4 and population growth and aging will
maintain the ongoing disease burden.4
The 5-year relative survival rates from lung cancer in
New Zealand of 9.5% for males and 11% for females (1994–
2003)5 are higher than those in the United Kingdom: 6% for
males and 7.5% for females (1998–2001).6 However, these
rates are low by comparison with Australia (males: 12%;
females 15%; 1999–2003; NSW),7 the United States (13 and
17%, respectively; 1996–2002),8 and Canada (14 and 18%,
respectively, 1995–97).9
Whereas the high mortality from lung cancer world-
wide is attributed to the late presentation of lung cancer
patients, which precludes curative resection, the factors un-
derlying international variations in survival are thought to
relate more to deficiencies in cancer care, such as delays in
management or the failure to offer active treatment.10–12 The
inferior survival rates in the United Kingdom have histori-
cally been attributed to lower-quality care,12,13 although more
recently, higher levels of comorbidity and later presentation
in the United Kingdom have been considered as contributing
factors.14
Despite poor survival outcomes and speculation regard-
ing cancer management, there has not been a previous study
of patterns of care for patients with lung cancer in New
Zealand. Therefore, we undertook a retrospective study of
lung cancer presentation and secondary care management in
a large, representative region of New Zealand, with the
specific aim of determining the stage of disease at presenta-
tion and initial management. We then compared these data
with available international data.
PATIENTS AND METHODS
A cross-sectional study of persons with a diagnosis of
primary lung cancer (ICD-10 C33 and C34) in 2004 who
received a component of their initial management in second-
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ary care within the four district health boards (DHBs) of
Auckland and Northland was undertaken. These four (of New
Zealand’s 21) DHBs collectively comprised 1.5 million peo-
ple, constituting 37% of the New Zealand population. This
population base is serviced in the public health system by a
single regional oncology service, providing radiation oncol-
ogy (RO), medical oncology (MO), and cardiothoracic sur-
gery (CTS), but with separate respiratory services at each
DHB. In addition, the private system offers consultations in
all specialties, and treatment with surgery and chemotherapy,
but not radiation therapy (RT). The study period spanned
entry into secondary care until commencement of initial
anticancer treatment, or until a decision was made for sup-
portive care alone.
To determine eligible patients, relevant databases from
both the regional public and private health systems were
accessed for the period of January 2004 to June 2005. These
included listings of hospital admissions and discharges, tho-
racic surgery operation schedules, databases of cytohistopa-
thology, radiation oncology, palliative care, and regional
hospice services. The medical records of approximately 2700
potentially eligible cases were accessed. The majority of
these cases were ineligible because the diagnosis had not
been made in 2004. Cases were also excluded if their lung
cancer was managed entirely within primary care (13 cases)
or if the diagnosis of lung cancer was made after death (19
cases). Eligible cases identified from the regional databases
were then checked against a listing of cases provided by the
New Zealand Cancer Registry (NZCR). Discrepancies be-
tween listings were explored and resolved; these will be the
subject of another paper. Briefly, of the 565 cases in the
study, 490 cases were common to both listings, nine addi-
tional cases were identified from the NZCR, and the regional
databases identified 66 cases not contained on the NZCR
listing. However, a similar number on the NZCR listing (58
cases after elimination of a duplicate registration and cases
diagnosed after death) were not eligible for the study. Thus,
the two listings identified similar numbers of cases, although
the cases were not identical, because of definitional differ-
ences related especially to the date of diagnosis. Also, the
current study included cases managed within the region,
whereas the NZCR included only cases whose residential
address was within the region. Of the 58 ineligible cases on
the NZCR list, no information could be found in the regional
databases for 13 cases. It was unknown how many of these 13
cases were managed entirely within primary care and how
many were managed outside the region.
Data were accessed from electronic and paper medical
records. The National Health Index (NHI), a unique personal
identifier of all persons accessing the public health system in
New Zealand, was used to link information from different
sources. During the study period, some eligible persons
moved in or out of the study DHB regions. Data for these
persons were included for those components of management
that they received from the study DHBs. Paper records for 21
patients could not be located; however, some data were
extracted from the electronic records of these patients.
Data collection included demographic information,
presentation details, comorbidities, tumor, and manage-
ment details. Demographic data included date of birth, gen-
der, ethnicity, smoking history (ever smoked, current smoker,
pack-years), comorbidities, and presenting symptoms. The
New Zealand Deprivation Index 2001 (NZDep) was deter-
mined for each patient. This is a census-based, small-area
index of deprivation derived from the domiciliary address,
which measures socioeconomic deprivation on a scale of 1 to
10 (with 10 representing the most deprived level).
Comorbidities were recorded, grouped, and counted.
The number of comorbidities was determined by counting
each of the following categories as one comorbidity (irre-
spective of how many conditions the patient had in each
category): respiratory disease, cardiovascular disease (ex-
cluding controlled hypertension and hyperlipidemia), cere-
brovascular disease, other vascular disease, psychiatric dis-
orders, diabetes mellitus (other than diet controlled), other
cancer, or other potentially relevant disease (such as renal,
hematological, neurological, rheumatological, gastrointesti-
nal, and endocrine conditions). The maximum possible num-
ber of comorbidities was 8. Comorbidities were also scored
according to the internationally validated Charlston Comor-
bidity Index (CCI).15,16
Histological type (small-cell lung cancer [SCLC], car-
cinoid, non-small cell lung cancer [NSCLC], and NSCLC
subtype), clinicoradiological tumor stage at presentation to
secondary care, and pathological tumor stage for cases with
tumor resection were determined. Stage was assigned by one
author (GS) according to a retrospective review of the reports
of staging investigations (mainly chest x-ray, CT scan, bron-
choscopy, and mediastinoscopy). Radiological images were
not reviewed. SCLCs were staged according to the standard
definition of limited or extensive disease.17 All other cancers
were staged according to the UICC/AJCC TNM defini-
tions.17,18 To reduce bias, clinicoradiological tumor-stage
assignation was made without knowledge of the identity or
subsequent management of the case, or the pathological stage
where available. To check staging reliability, comparison was
made with two previous audits (one involving the respiratory
service at one of the DHBs, and the other a CTS audit).
Collectively, these two small audits had 92 cases in common
with the current study. Staging was the same as that assigned
in the study for all but 10 cases. These cases were restaged
(by G.S.), initially blind to the other audit’s staging and then
unblinded. Reasons for any discrepancies in staging were
identified and assessed. Differences were predominantly at-
tributable to (i) the deliberate downstaging policy used in the
study when uncertainty existed with respect to lymph node
involvement or the presence of distant metastases, or (ii)
earlier timing of staging (i.e., at diagnosis) used in the study.
No changes in study staging were made as a result of this
check, because the investigators were satisfied with the stag-
ing assigned.
Management data included referrals during the study
period to anticancer services (CTS, RO, and/or MO) and to
palliative care services, the intent of treatment (curative or
palliative), initial treatment received, and rejection of recom-
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mended management. In some cases, the intent of manage-
ment was not recorded in the medical records but was
determined retrospectively by the authors on the basis of the
type of treatment initiated. If curative treatment had been
commenced, the intent was deemed to be curative, despite
any subsequent conversion to palliative treatment.
In this study, treatment refers only to the initial man-
agement after diagnosis; it does not account for treatments
provided later in the course of an illness. For example, if an
initial decision was made to provide supportive care alone
but, at a later time, the patient received anticancer treatment,
such treatment was not included in this study. The type of
management was classified as either anticancer or supportive.
Anticancer treatment implied tumor excision, or cytoreduc-
tion of the cancer with chemotherapy or RT, and was deliv-
ered with either curative or palliative intent. By contrast,
supportive care implied symptomatic management without
active treatment of the cancer and was always delivered with
palliative intent.
ANALYSIS
To minimize errors, data were double entered. Reliabil-
ity was assessed by cross-checking the study data with data
from the NZCR and also from two smaller audits that con-
tained a number of matching cases and information fields. To
ensure consistency in data collection, staging, and adherence
to definitions, data for 30 cases accrued early in the study
were recollected for comparison, and random checks were
performed on other cases. Data were analyzed using SPSS
version 14. Data analysis included 2 tests to assess relation-
ships between categorical variables, and univariate and mul-
tivariate logistic regression analysis to assess the main factors
associated with the receipt of any anticancer treatment, as
well as those associated with the receipt of potentially cura-
tive treatments. Variables entered into the multivariate logis-
tic regression models were stage of disease at presentation,
age of the patient at diagnosis, gender, NZDep, number of
comorbidities, tumor type (NSCLC, SCLC, carcinoid, clini-
coradiological diagnosis), any component of secondary care
within the private sector, and discussion of the case at a
formally convened multidisciplinary meeting (MDM).
Comparison of the study findings with overseas data
was made following a literature search. Medline and Embase
databases were searched using MeSH terms, and relevant
articles were accessed. The international data presented in
this paper were selected on the basis of recency and compa-
rability of the data sets.
Ethical approval for this study was provided by the
Northern X Regional Ethics Committee.
RESULTS
Characteristics of the Cases
A total of 565 eligible cases were identified. The
characteristics of the cases are shown in Table 1. Although
lung cancers occurred across all NZDep scores, the propor-
tion of cases was greatest in the most socioeconomically
deprived levels, with 32% of cases from NZDep 9 to 10 (p 
0.001). Approximately 13% of cases had some component of
their secondary care management within the private sector
during the study period. Comorbidities were common, with
81% of cases having a recorded medical condition that could
potentially influence management decisions. The categories
of comorbidities recorded in the study are presented in Table
1. The number of comorbidities ranged from 0 to 7, and CCI
scores ranged from 0 to 8.
The most common mode of presentation leading to a
diagnosis of lung cancer involved symptoms of locoregional
disease (65%). Another 15% presented with symptoms from
metastases, 1% presented with paraneoplastic symptoms, and
20% presented with an incidental finding of a lung mass on
radiological imaging. The latter included asymptomatic pa-
tients and those with nonspecific symptoms being investi-
gated for other conditions, and some cases under regular
surveillance for other respiratory conditions.
Tumor Characteristics
Table 2 presents the tumor characteristics and clinico-
radiological stages of disease at presentation. Histological
diagnoses were obtained in 85% of cases; the diagnoses were
70% NSCLC, 13% SCLC, and 2% carcinoid. The remaining
15% of cases were diagnosed using clinical and radiological
criteria. Synchronous primary tumors were suspected in 14
cases. The records contained sufficient information to stage
all SCLC and 96% of NSCLC. Subsequently, unless other-
wise specified, stage refers to clinicoradiological stage at
diagnosis. There was a high proportion of advanced stage at
presentation: 65% of SCLC cases presented with extensive
disease, and 59% of all cases staged as NSCLC presented
with either stage IIIB or IV disease.
Management
Diagnostic Methods and Investigations
Diagnostic tissue was obtained in 35% of cases by
bronchoscopy, in 22% by CT-guided fine-needle aspiration of
the primary tumor, in 14% by biopsy of a metastasis, in 6%
by aspiration of pleural fluid, in 4% by thoracotomy, and in
4% by other means such as sputum cytology, mediastinos-
copy, or pericardial tap. There was no histological diagnosis
for 87 cases (15%), comprising 68 cases (12%) for which a
histological diagnosis was not attempted and 19 cases (3%)
with nondiagnostic tissue.
Referral for Treatment
Table 3 shows the management of the cases overall and
by tumor type. Approximately 70% of all cases were referred
to one or more of the three anticancer services.
Of patients who did not receive anticancer treatment,
41% were referred to an anticancer service and 78% were
seen by a respiratory physician. All patients who received
anticancer treatment were seen by an anticancer service, and
91% had been seen by a respiratory specialist. Of those
referred to an anticancer service, 71% received anticancer
treatment; 75% of cases referred to CTS underwent tumor
resection, 66% referred to RO received radiation therapy, and
23% referred to medical oncology received chemotherapy.
Overall, 20% of cases were treated with curative intent,
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representing 38% of those who received anticancer treatment.
Discussion at a formally convened MDM occurred for 28%
of cases (142 NSCLC, three clinicoradiological, six carci-
noid, and seven SCLC cases). Early-stage NSCLC cases were
significantly more likely to be discussed than later-stage
cases: 52% of NSCLC cases discussed at an MDM had stage
I/II, 26% had stage III, and 21% had stage IV disease (p 
0.001).
TABLE 1. Characteristics of All Study Cases: Those Who Received Anticancer Treatment with
Either Curative or Palliative Intent, and Those Managed with Supportive Care Alone
Totala
(565 cases)
Curative
Treatment
(109 cases)
Palliative
Treatment
(176 cases)
Supportive
Care Alone
(271 cases)
n % n % n % n %
Age (yr)
60 121 21 34 31 55 31 29 11
60–69 165 29 38 35 60 34 63 23
70–79 176 32 30 28 45 26 99 37
80 103 18 7 6 16 9 80 30
Male gender 311 55 53 49 104 59 148 55
Smoking status
Current smoker 232 41 42 39 93 53 94 35
Ex-smoker 271 48 55 50 72 42 139 51
Never smoker 52 9 12 11 11 6 28 10
Unknown 10 2 0 0 0 0 10 4
NZDep* deciles
1–2 (low deprivation) 73 13 16 15 24 14 32 12
3–4 91 16 27 25 27 15 36 13
5–6 90 16 22 20 23 13 44 16
7–8 130 23 21 19 46 26 60 22
9–10 (high deprivation) 178 32 23 21 56 31 97 36
Unknown 3 2
Comorbidities
Any relevant 455 81 84 77 133 76 233 86
Cardiovascular 212 38 36 33 51 29 123 45
Cerebrovascular 88 16 8 7 20 11 59 22
Other vascular 62 11 9 8 15 9 38 14
Respiratoryb 296 52 53 49 83 47 156 58
COPD 267 47 49 45 78 44 137 51
Tuberculosis 22 4 6 6 4 2 11 4
Other lung disease 59 10 8 7 12 7 39 14
Previous lung cancer 6 1 2 2 1 1 3 1
Diabetes mellitusc 75 13 14 13 21 12 39 14
Psychiatric disorder 50 9 8 7 9 5 32 12
Alcohol abuse 48 9 14 13 11 6 28 10
Another cancer 92 16 24 22 22 13 45 17
Charlston comorbidity index
0 157 28 32 30 61 35 58 22
1 195 35 41 38 66 38 86 32
2 211 37 36 33 48 27 125 47
Unknown 2 1 2 1
No. of comorbidities
0 110 20 25 23 43 24 38 14
1 157 28 33 30 61 35 60 22
2 145 26 30 28 46 26 69 26
3 153 27 21 19 26 15 104 38
Because of rounding, percentages may not add up to 100. NZDep, New Zealand Deprivation Index, 2001. aNine cases are not included
in the three treatment subcategories (seven left the area before treatment, and two were shown on subsequent histology exams not to have
cancer). bSome patients had multiple respiratory diseases. cNot including diet-controlled diabetes.
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There was evidence in the records that 52 patients
(9% of cases) declined some aspect of recommended
management. This comprised 10 patients who refused
investigation, 18 who declined referral to an anticancer
specialist, 14 who declined the offer of anticancer treat-
ment, 7 who failed to attend a booked oncology appoint-
ment (and declined further appointments), and 3 who
cancelled booked treatment.
Treatment of SCLC
Of the 26 cases with limited-stage SCLC, two left the
area before treatment, and 15 were managed with curative
intent, consisting of platinum-based chemotherapy and
then consolidation RT to intrathoracic disease. Prophylac-
tic cranial irradiation was delivered in seven of these cases.
Of the 57 cases of SCLC managed palliatively (9 with
limited stage and 48 with extensive stage), 20 received
chemotherapy, 8 received RT, and 29 received supportive
care alone.
Treatment of Tumors Staged as NSCLC
As anticipated, the treatment intent of these cases (i.e.,
histologically verified NSCLC, tumors diagnosed on clinico-
radiological evidence, and carcinoid tumors) was stage de-
pendent (p  0.001), as shown in Table 4. Of the 142 cases
with stage I/II tumors, 79 cases (56%) were treated with
curative intent; 64 cases had surgery alone, three had post-
operative adjuvant chemotherapy, two had postoperative ad-
juvant RT, nine had RT alone, and a single case had RT with
concurrent chemotherapy. Of the 44% of stage I/II NSCLC
treated palliatively, one third (21 cases) received palliative
anticancer treatment, and the remaining 40 cases received
supportive care alone. Of the 14 stage III cases (seven stage
IIIA, seven IIIB) managed curatively, treatment consisted of
TABLE 2. Tumor Characteristics Overall, and by Gender
Male Female Total
Tumor Type n % n % n %
NSCLC
NSCLC Subtype
Total 220 71 178 70 398 70
Adenocarcinoma 79 25 108 43 187 33
Squamous 102 33 41 16 143 25
Large-cell undifferentiated 7 2 5 2 12 2
NSCLC not further defined 26 8 21 8 47 8
Bronchoalveolar carcinoma 4 1 2 1 6 1
Adenoidcystic carcinoma 1 0.3 0 0 1 0.2
Tumor stage(clinicoradiological stage at diagnosis)
Total 220 71 178 70 398 70
Stage I 47 21 45 25 92 23
Stage II 12 6 10 6 22 6
Stage IIIA 20 9 21 12 41 10
Stage IIIB 38 17 34 19 72 18
Stage IV 93 42 64 36 157 40
Unstaged 10 5 4 2 14 3
Clinicoradiological diagnosis
Total 44 14 40 16 84 15
Stage I 7 16 9 23 16 19
Stage II 2 5 1 3 3 4
Stage IIIA 7 16 5 13 12 14
Stage IIIB 1 2 3 8 4 5
Stage IV 23 52 17 43 40 48
Unstaged 4 9 5 13 9 11
Small-cell lung cancer
Total 42 14 32 13 74 13
Limited 16 38 10 31 26 35
Extensive 26 62 22 69 48 65
Carcinoid
Total 5 2 4 2 9 2
Stage I 4 80 3 75 7 78
Stage II 1 20 1 25 2 22
NSCLC, non-small cell lung cancer.
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surgery alone in five cases, radiation therapy alone in two
cases, and combination modalities in seven cases. All cases
with stage IV disease were managed palliatively. The major-
ity of these (60%) received supportive care alone, 34%
received RT, and 6% received chemotherapy.
Factors Influencing Management
Decisions regarding management were influenced by a
variety of patient- and tumor-related factors, particularly
stage of disease, age of the patient, and level of comorbidity.
Unadjusted and adjusted odds ratios for factors influencing
the receipt of any anticancer treatment are listed in Table 5.
Figure 1 shows the influence of age on referral and
treatment decisions (Figure 1A), and the relationship between
age and comorbidity (Figure 1B). As age at diagnosis in-
creased, the proportion of patients with NSCLC or clinicora-
diological diagnoses who were referred to an anticancer
service or who received anticancer treatment, particularly
with curative intent, decreased. However, referral for anti-
cancer treatment for patients with SCLC, though most likely
in the youngest age group (60 years), did not seem to be
influenced by age for those greater than 60 years of age at
diagnosis. Although the level of comorbidity increased with
age for each category of comorbidity (Figure 1B), the inverse
relationship between age and treatment was not fully ex-
plained by the presence of comorbidities or stage of disease
(Table 5). There was an 80% reduction in the odds of
receiving any anticancer treatment for those aged 80 years or
older compared with those younger than 60 years at diagno-
sis, after adjusting for stage, comorbidity, gender, NZDep,
tumor type, private care, and discussion at an MDM.
The odds of receiving anticancer treatment were re-
duced by 70% for cases with advanced disease (stage IIIB/IV
NSCLC or extensive SCLC) compared with those with early
disease (stage I–IIIA NSCLC or limited SCLC) after adjust-
ing for other factors. As the number of comorbidities in-
creased, the odds of receiving anticancer treatment also
decreased after adjusting for other factors. The greatest re-
duction in the likelihood of receiving anticancer treatment
occurred with three or more comorbidities. In particular,
cardiovascular disease decreased the likelihood of receiving
anticancer treatment. When comorbidity was scored accord-
ing to the CCI (rather than grouped into disease categories or
counted), the CCI was not significant in either univariate or
multivariate analysis.
Apart from stage, age, and comorbidity, other factors
influencing whether patients received anticancer treatment
were lack of a histological diagnosis, some component of
initial secondary care management within the private sector,
and discussion at an MDM. For those patients who received
anticancer treatment, factors that independently influenced
whether they received treatment with curative or with pallia-
tive intent were stage of disease, age of 80 years or older, and
MDM discussion. Other factors such as lack of a histological
diagnosis, number of comorbidities, and private care did not
influence the intent of the treatment once the decision had
been taken to give active treatment.
International Comparison
Table 6 presents some comparative data from the cur-
rent study and relevant international studies. Cases in the
current study had similar ages, smoking histories, socioeco-
nomic status, and tumor types to other lung cancer cases
reported internationally.14,19–24 The diagnostic and staging
investigations performed in the study were similar to those
performed elsewhere, except that positron emission tomog-
raphy scanning was unavailable in New Zealand. The major
factors reported to influence treatment decisions internation-
TABLE 3. Management of Cases, Overall and by Tumor Type
Overall
(565 cases)
NSCLC
(396 cases)
Clinicoradiologial
(86 cases)
Carcinoid
(9 cases)
SCLC
(74 cases)
n % n % n % n % n %
Referrals during study period
Respiratory physician 477 84 353 89 51 59 9 100 64 87
Anticancer service 401 71 321 81 11 13 8 89 61 82
Cardiothoracic surgery 105 19 94 24 1 1 8 89 2 3
Radiation oncology 249 44 211 53 8 9 1 11 29 39
Medical oncology 177 31 116 29 3 3 2 22 56 76
Palliative care 281 50 186 47 47 55 0 0 48 65
Intent of management
Curative 109 19 85 22 1 1 8 89 15 20
Palliative 447 79 305 77 84 98 1 11 57 77
Not applicablea 9 2 6 2 1 1 0 0 2 3
Discussed at multidisciplinary meeting 158 28 142 36 3 3 6 67 7 10
Anticancer treatment 285 50 227 58 7 8 8 89 43 58
Not applicablea 9 2 6 2 1 1 0 0 2 3
NSCLC, histologically verified non-small cell lung cancer (two cases with initial NSCLC histology were found, on subsequent
histological review, not to have cancer); SCLC, small-cell lung cancer (73 cases were histologically verified, and one diagnosis was made
on the basis of a pathognomonic paraneoplastic syndrome). a Not applicable refers to (i) seven cases that moved out of the study area before
treatment, and (ii) two cases found not to have lung cancer on subsequent histological review.
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ally were stage of the disease, age of the patient, and comor-
bidity burden; this is consistent with the findings of the
current study.13,23,25,26
DISCUSSION
This is the most comprehensive analysis of lung cancer
management conducted in New Zealand. It examined stage at
presentation, comorbidities, and initial anticancer treat-
ment—factors that may have a bearing on the lower survival
rate from lung cancer in New Zealand than in other countries
such as Australia, Canada, and the United States.
The demographic profile of the study cases was similar
to those reported internationally, although a greater propor-
tion was female (Table 6). This is consistent with the higher
smoking rates of New Zealand women compared with
women in Australia, the United States, and Canada.27 How-
ever, the international comparative data covered an earlier
time period (1998–2003); this may reflect the continuing
rise in the incidence of female lung cancer in developed
countries.22,28
This cohort was characterized by high levels of comor-
bidity. Although the comorbidity burden in lung cancer
patients is generally recognized to be high26,29 because of
concomitant smoking-related diseases,21,30 many patterns-of-
care studies have not included comorbidity data. The record-
ing of comorbidities in clinical records may be variable and
subject to ascertainment bias, comorbidities may be difficult
to classify and grade despite internationally validated scores,
and increasing numbers of comorbidities may have multipli-
cative rather than additive effects.26
Despite these problems, an attempt was made to eval-
uate the impact of comorbidity on management decisions and
to compare the level of comorbidity in study cases with those
reported elsewhere. This study cohort had higher comorbidity
levels than those reported for lung cancer patients elsewhere,
despite similarities in age at diagnosis, smoking history, and
socioeconomic status. This applied when comorbidities were
either grouped according to disease categories or scored
according to the CCI. Although high comorbidity levels may
have led to more conservative management decisions and less
TABLE 4. Type of Management According to Tumor Type and Clinicoradiological Stage at
Diagnosis
Curative Treatment Palliative Treatment Supportive Care Not Applicablea
Clinical Stage of Disease n % n % n % n %
Overall (565 cases)
Total 109 19 176 31 271 48 9 2
NSCLC (396 cases)
Total 85 22 142 36 163 41 6 2
I 57 62 15 16 19 21 1 1
II 13 62 5 24 2 10 1 5
IIIA 7 17 12 29 21 51 1 2
IIIB 6 8 35 49 30 42 1 1
IV 0 0 74 47 82 53 0 0
Unstaged 2 14 1 7 9 64 2 14
Clinicoradiological (86 cases)
Total 1 1 6 7 79 91 1 1
I 1 6 1 6 14 88 0 0
II 0 0 0 0 4 100 0 0
IIIA 0 0 0 0 11 92 1 8
IIIB 0 0 1 25 3 75 0 0
IV 0 0 4 10 37 90 0 0
Unstaged 0 0 0 0 10 100 0 0
Carcinoid (9 cases)
Total 8 89 0 0 1 11 0 0
I 6 86 0 0 1 14 0 0
II 2 100 0 0 0 0 0 0
SCLC (74 cases)
Total 15 20 28 38 29 39 2 3
Limited 15 58 5 19 4 15 2 8
Extensive 0 0 23 48 25 52 0 0
NSCLC, non-small cell lung cancer; SCLC, small-cell lung cancer; curative treatment, anticancer treatment with curative intent;
palliative treatment, anticancer treatment with palliative intent; supportive care, supportive care alone (no anticancer treatment). aNot
applicable refers to (i) seven cases that moved out of the study area before treatment, and (ii) two cases found not to have lung cancer on
subsequent histological review.
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anticancer treatment, the impact of comorbidities on thera-
peutic decision making could not be accurately ascertained in
this retrospective study. Variable recording and measuring of
comorbidity could be responsible for the observed differences
in comorbidity levels between the studies. A U.S. study that
determined the number of comorbidities using a different count-
ing system reported 88% of cases with at least one comorbidity,
as compared with 81% in the current study.31 Prospective
evaluation of comorbidities using a standardized scoring system
is required for meaningful comorbidity comparison.
In common with overseas results, this cohort was char-
acterized by a high proportion of cases with advanced dis-
ease. Possible reasons for the advanced stage of lung cancer
patients could include barriers to accessing primary care or to
delays within primary care; examination of such issues was
beyond the scope of the current study. The staging investi-
gations performed were similar between studies, except for
the lack of positron emission tomography scanning, which
may have led to understaging of the New Zealand patients.
Older patients were significantly less likely to be in-
vestigated or referred, or to receive anticancer treatment
(palliative or curative). Although age requires consideration,
because of reduced life expectancy and physiological changes
associated with increased toxicity from chemotherapy and
increased morbidity and mortality from surgery,32,33 elderly
patients should not automatically be excluded from poten-
tially curative management. Improved assessment of elderly
patients, advances in surgical procedures and postoperative
care, and the availability of “elderly-friendly” chemothera-
peutic agents have minimized the adverse effects of treat-
ment.34,35 Long-term survival for elderly patients who survive
surgery is similar to that for younger patients34; radiation
therapy is well tolerated even in those older than 80 years,36
and the use of a combination of carboplatin and etoposide in
TABLE 5. Factors Influencing Receipt of Any Anticancer Treatment (Either with Curative or with
Palliative Intent)
Unadjusted Odds of
Anticancer
Treatmenta
Adjusted Odds of
Anticancer
Treatmentb
p Value Odds 95% CI p Value Odds 95% CI
Agec (yr) <0.0001
60 1 1
60–69 0.015 0.5 0.3–0.9 0.163 0.7 0.4–1.2
70–79 <0.001 0.3 0.2–0.5 0.001 0.3 0.2–0.6
80 <0.001 0.1 0.05–0.2 <0.0001 0.2 0.1–0.4
Gender NS NS
Male 1 1
Female 0.899 1.0 0.7–1.4 0.9 1.0 0.6–1.5
NZDep decilesd NS NS
1–5 1 1
5–10 0.066 0.7 0.5–1.0 0.773 0.9 0.6–1.5
Number of comorbidities <0.0001 0.7 0.6–0.8 0.004 0.8 0.7–0.9
Tumor type
NSCLC 1 1
Small cell 0.789 1.1 0.6–1.8 0.871 1.0 0.5–1.7
Carcinoid 0.099 5.8 0.7–46.9 0.696 0.646 0.1–5.8
Clinicoradiological <0.0001 0.05 0.02–0.1 <0.0001 0.1 0.0–0.3
Stage of disease
Early: I, II, IIIA, Lim 1 1
Late: IIIB, IV, Ext <0.0001 0.4 0.3–0.6 <0.0001 0.3 0.2–0.5
Private care
Total public care 1 1
Some private care <0.0001 3.9 2.1–6.9 0.002 2.113 1.5–6.3
MDM
Not discussed 1 1
MDM discussed <0.0001 6.3 4.0–9.7 <0.0001 3.0 1.7–5.0
NZDep, New Zealand Deprivation Index; NSCLC, non-small cell lung cancer; MDM, multidisciplinary meeting; non-bold p values, non
significant p values; bold p values, significant p values; NS, not significant.
a
Odds of receiving anticancer treatment (with either curative
or palliative intent) in separate logistic regression models; bodds of receiving anticancer treatment (with either curative or palliative
intent) in a multivariate logistic regression model (i.e., the odds of treatment after adjusting for all other factors in the model).
Variables included in the model were age, gender, NZDep, number of comorbidities, tumor type, stage, private care, and
discussion at an MDM. cAge was significant when entered into the model as a continuous variable or in age groups. dNZDep was
not significant when entered as a continuous variable or grouped into categories.
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elderly patients with SCLC has produced a high (80–90%)
response rate with acceptable toxicity.34
International studies also have reported inverse associ-
ations between age and treatment rates.24,32,37,38 Although
patient preferences and physician attitudes may be responsi-
ble for such associations, confounding is difficult to exclude.
Uncontrolled factors such as performance status and lung
function, and underestimation of the comorbidity burden in
older patients, could result in residual confounding. Thus, it is
difficult to determine the extent to which chronological age
influenced management decisions in the current study.
Initial secondary care management of study cases was
comparable with that in the United Kingdom, but it differed
substantially from that reported in Australia and the United
States. Differential access to specialist care and treatment has
been considered a major factor contributing to international
variations in lung cancer survival.13,39–42 The low 5-year
relative survival rate in the United Kingdom (7%) compared
with those of other European Union countries (8–15%) has
been attributed to the lower rate of anticancer treatment,
especially surgical resection, in the United Kingdom.11,13,43,44
Surgical resection, which offers the best survival advantage
for early-stage NSCLC patients,41 was performed in only
14% of cases in this cohort, whereas radical RT, the other
potentially curative modality, was given in only 6% of cases.
Management was palliative in 80% of cases, which included
44% of cases with early-stage NSCLC. A substantial propor-
tion of cases (48%) received supportive care alone.
Referral to an anticancer service is essential for im-
proved survival, yet in the current study, only 70% of cases
were referred. Referral patterns may be influenced by insti-
tutional, doctor, or patient factors. Nihilistic attitudes (partic-
ularly by respiratory physicians), misinformation, or outdated
knowledge have been considered responsible for low referral
and treatment rates elsewhere; these factors may also be
important in New Zealand.24,44–49
International guidelines stress the importance of
MDMs.41 In the current study, MDM refers to a formally
convened multidisciplinary meeting, consisting of physicians
from a variety of specialties including respiratory, medical
and radiation oncology, cardiothoracic surgery, and radiol-
ogy. Such meetings have the potential to address the nihilism
of individuals and professional groups and to enhance con-
sistency in therapeutic decision making.49 In this cohort, only
36% of NSCLC cases, 4% of cases with a clinicoradiological
diagnosis, and 10% of SCLC cases were discussed at an
MDM. Patients in whom curative therapy was not proposed
were much less likely to be discussed at an MDM (p 
0.001). Bias toward discussion of cases with resectable early-
stage NSCLC has also been reported elsewhere.10 Such bias
emphasizes the need to educate practitioners about the role of
multidisciplinary care in advanced disease.10
Higher active treatment rates have been observed in
cases discussed at MDMs in Australia.10 Discussion at an
MDM was an independent factor determining receipt of any
specific anticancer treatment, as well as potentially curative
therapy. Although this positive association could be attribut-
able to selection bias, discussion of all cases at an MDM may
result in higher treatment rates and, hence, improve overall
outcomes.
Factors such as the availability of appropriate special-
ists and specialist services may also influence referral and
treatment patterns. In New Zealand, access to RO has been
impaired by lengthy treatment waiting times associated with
staffing problems, and access to chemotherapy services has
FIGURE 1. (A) Influence of age on anticancer referral, anti-
cancer treatment, and curative intent for (i) cases with either
a histological diagnosis of NSCLC or a clinicoradiological di-
agnosis of lung cancer, and (ii) cases with SCLC. (B) Associa-
tion of patient age (all cases) with any potentially relevant
comorbidity, respiratory disease, cardiovascular disease, or
other comorbidity (i.e., other than respiratory or cardiovas-
cular disease).
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TABLE 6. Comparison of the Current Study with International Studies
New Zealand:
Current Study Australia United States
United
Kingdom Europe
Mean (SD) age in years 68 (11) 68 (11)10 6623 69 (10)14 67 (10)14(Italian center)
Median age in years 69 6824 6723, 7019 6835
Females (%) 45 3010,25,51, 3250,
3554
3919,23 3445, 4114,56 2557
(Italian center)14
Smokers 89 9010 9123 8831 9214
Current (%) 41 21 38 42 53 87
Ex-smokers (%) 48 69 53 46 39 46
Never smokers (%) 9 10 4 8 4 41
Unknown (%) 2 5 4 4 13
Mean (SD) pack-years 37 (24) 53 (36)31
Comorbidities (%) (Italian center)14
Any 81 6123 8831 7314 64
Respiratory 52 37 34
Cardiovascular 38 30
Diabetes 14 13
Charlston Comorbidity Index (Netherlands)26
0 28
1 35 34
2 37 33
Unknown 1 27
No. of comorbidities 6
0 20 1231
1–2 53 34
3 27 54
Tumor type (%) (Italian center)14
Clinicoradiological diagnosis 15 810, 924, 4–1251,52 123 3445 2814 18
Histologically confirmed 85 9124 9923 10031 66 72 82
NSCLC 70 7524 84 88 56 55 70
Adenocarcinoma 33 25 33 16 25
Squamous carcinoma 25 32 26 25 35
Large-cell carcinoma 2 6 4 8 2
Unspecified NSCLC 8 1624 19 24 6 8
Other 2 2 2
SCLC 13 15 12 11 17 12
Carcinoid 2
NSCLCa (%) (Italian center)14
Localized/early/I–II 29 2024 2253 1619 2731 2514 31
Loc advanced/III 27 32 9 37 29 71 69
Metastatic/IV 40 28 39 39 34
Unstaged 4 20 30 8 104
SCLC (%)
Limited 35 5024 4519
Extensive 65 50 55
Unstaged 0 5
Referral (%)
Respiratory 85 6124 5445 7513
Cardiothoracic surgery 19 25 21
Radiation oncology 45 56 45
Medical oncology 32 36
Initial anticancer treatment (%) 50 6854 4945 5014 7514
(Continued)
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been limited by service constraints and lack of access to
certain chemotherapeutic agents as a consequence of the
policies of the government pharmaceutical-purchasing
agency. Rationing of drugs and services, and low numbers of
radiation and medical oncologists per capita, have been
thought to contribute to the poorer outcomes in the United
Kingdom.12
The explanation of the higher rate of anticancer
treatment among patients who received some component
of care in the private sector, independent of stage and
comorbidity, remains speculative. It may relate to different
attitudes and expectations of patients who seek private care
or to the attitudes of their doctors, or it could relate to other
factors such as residual confounding by comorbidity or the
ability to pay for treatment not considered appropriate in
public hospitals.
Nine percent of patients declined recommended man-
agement; this may be an underestimate, because of a lack of
documentation. Other patterns-of-care studies generally have
not documented patient decisions regarding management,
although failure to accept chemotherapy in advanced NSCLC
has been reported.44 Although patient and cultural prefer-
ences should guide decision making, it is important to ensure
that such decisions are informed and are not based on mis-
understandings or inadequate knowledge.
This is the first study of the patterns of secondary care
of lung cancer patients in New Zealand. Because the study
was large, comprehensive, and representative, encompassing
37% of the population, its findings are likely to be relevant
nationally. Because of mandatory reporting of cancer in New
Zealand, case ascertainment was high. However, because the
current study focused on secondary care management, pa-
tients managed entirely within primary care or diagnosed
after death were excluded. Although the number of these
patients was small (0.5% of cases), they are likely to
represent a select group with differing characteristics from
the majority of cases who were diagnosed before death and
managed within secondary care. Although beyond the scope
of this study, further investigation of such cases is warranted
and may identify barriers to primary and/or secondary care.
Also, retrospective reviews are limited by the extent and
quality of the recorded information. Although the almost
complete staging of tumors was a particular strength of this
study, staging was performed retrospectively by one investi-
gator, from the radiological reports, without the benefit of
reviewing the radiological imaging. Reasons underlying pa-
tient refusal of management could not be determined in this
study, and inconsistency of recording precluded the inclusion
of performance status and weight loss and hampered assess-
ment of comorbidities. Prospective studies are required to
clarify these issues.
CONCLUSIONS
A high proportion of study cases had recorded comor-
bidities, presented with advanced disease, and were neither
referred nor considered for active anticancer treatment. Fac-
tors influencing whether patients received anticancer treat-
ment were stage, age, number of comorbidities, lack of a
histological diagnosis, private care, and discussion at an
MDM. Younger age, MDM discussion, and some private care
were independently associated with a more aggressive treat-
ment approach.
Comparison with international data suggests that cases
in the current study had demographic characteristics, smok-
ing histories, tumor characteristics, and stage at presentation
similar to those in other developed countries. Treatment rates
were considerably lower than those in countries such as
Australia and the United States, and the differences in man-
agement could not be fully explained by stage of disease or
levels of comorbidity.
Thus, there may be scope for more patients in New
Zealand to receive anticancer treatment, especially with cur-
ative intent. Discussion of cases at an MDM has the potential
to standardize care and to increase active treatment rates.
Differences in secondary care management of lung cancer
patients seem to contribute to the previously reported poor
survival outcomes in New Zealand relative to those in Aus-
tralia and the United States.
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